文献速递肝病

格卡瑞韦/哌仑他韦8周方案治疗初治慢性丙肝1-6型合并代偿期肝硬化

Glecaprevir/pibrentasvir for 8 weeks in treatment-naïve patients with chronic HCV genotypes 1-6 and compensated cirrhosis: The EXPEDITION-8 trial.
PubMed 文献 · J Hepatol · 2019-11-02

EXPEDITION-8是一项单臂多中心IIIb期试验,评估格卡瑞韦/哌仑他韦每日一次8周方案治疗初治慢性HCV基因1-6型合并代偿期肝硬化患者。共入组343例,基因1-6型患者PP人群SVR12达99.7%(334/335,95%CI 98.3-99.9),ITT人群97.7%(335/343,95%CI 96.1-99.3),所有主要和关键次要疗效分析均达到预设阈值。安全性良好,常见不良事件为疲劳、瘙痒、头痛和恶心,无因不良事件停药。

要点

  • 8周格卡瑞韦/哌仑他韦在初治代偿期肝硬化HCV基因1-6型患者中SVR12达99.7%(PP)和97.7%(ITT)。
  • 疗效与12周方案历史SVR12率相似,所有主要和关键次要分析均达到预设阈值。
  • 安全性良好,常见不良事件为疲劳、瘙痒、头痛和恶心,无因不良事件停药。

核心结论

  • 8周格卡瑞韦/哌仑他韦治疗初治慢性HCV基因1-6型合并代偿期肝硬化患者耐受性良好,SVR12率与12周方案相似。

研究设计与样本

  • EXPEDITION-8为单臂、多中心、IIIb期试验,共入组343例初治慢性HCV基因1-6型合并代偿期肝硬化患者。

主要发现

  • 基因1-6型患者PP人群SVR12为99.7%(334/335,95%CI 98.3-99.9),ITT人群为97.7%(335/343,95%CI 96.1-99.3)。
  • 1例基因3a型患者在治疗结束后第4周复发(0.3%)。
  • 常见不良事件(≥5%)为疲劳(9%)、瘙痒(8%)、头痛(8%)和恶心(6%);严重不良事件发生率2%(均与药物无关)。
  • 无不良事件导致研究药物停药,临床显著实验室异常少见。

关键数值与推荐

  • 主要和关键次要疗效分析均达到基于12周格卡瑞韦/哌仑他韦历史SVR12率预设的疗效阈值。

临床怎么用

  • 8周格卡瑞韦/哌仑他韦可作为初治慢性HCV基因1-6型合并代偿期肝硬化患者的简化治疗选择。
  • 该方案可能简化护理流程,使非专科医疗人员也能治疗此类患者,助力全球HCV消除。

局限性

  • 单臂设计,无同期对照,疗效比较基于历史数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Eight-week glecaprevir/pibrentasvir leads to high rates of sustained virological response at post-treatment week 12 (SVR12) across HCV genotypes (GT) 1-6 in treatment-naïve patients without cirrhosis. We evaluated glecaprevir/pibrentasvir once daily for 8 weeks in treatment-naïve patients with compensated cirrhosis. METHODS: EXPEDITION-8 was a single-arm, multicenter, phase IIIb trial. The primary and key secondary efficacy analyses were to compare the lower bound of the 95% CI of the SVR12 rate in i) patients with GT1,2,4-6 in the per protocol (PP) population, ii) patients with GT1,2,4-6 in the intention-to-treat (ITT) population, iii) patients with GT1-6 in the PP population, and iv) patients with GT1-6 in the ITT population, to pre-defined efficacy thresholds based on historical SVR12 rates for 12 weeks of glecaprevir/pibrentasvir in the same populations. Safety was also assessed. RESULTS: A total of 343 patients were enrolled. Most patients were male (63%), white (83%), and had GT1 (67%). The SVR12 rate in patients with GT1-6 was 99.7% (n/N = 334/335; 95%CI 98.3-99.9) in the PP population and 97.7% (n/N = 335/343; 95% CI 96.1-99.3) in the ITT population. All primary and key secondary efficacy analyses were achieved. One patient (GT3a) experienced relapse (0.3%) at post-treatment week 4. Common adverse events (≥5%) were fatigue (9%), pruritus (8%), headache (8%), and nausea (6%). Serious adverse events (none related) occurred in 2% of patients. No adverse event led to study drug discontinuation. Clinically significant laboratory abnormalities were infrequent. CONCLUSIONS: Eight-week glecaprevir/pibrentasvir was well tolerated and led to a similarly high SVR12 rate as the 12-week regimen in treatment-naïve patients with chronic HCV GT1-6 infection and compensated cirrhosis. TRIAL REGISTRATION: ClinicalTrials.gov, NCT03089944. LAY SUMMARY: This study was the first to evaluate an 8-week direct-acting antiviral (DAA) regimen active against all major types of hepatitis C virus (HCV) in untreated patients with compensated cirrhosis. High virological cure rates were achieved with glecaprevir/pibrentasvir across HCV genotypes 1-6, and these high cure rates did not depend on any patient or viral characteristics present before treatment. This may simplify care and allow non-specialist healthcare professionals to treat these patients, contributing to global efforts to eliminate HCV.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Brown RS, Buti M, Rodrigues L, et al. Glecaprevir/pibrentasvir for 8 weeks in treatment-naïve patients with chronic HCV genotypes 1-6 and compensated cirrhosis: The EXPEDITION-8 trial. J Hepatol. 2019. PMID: 31682879. doi:10.1016/j.jhep.2019.10.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。